CymaBay Therapeutics, Inc. – LSE:0I5P.L
CymaBay Therapeutics stock price today
CymaBay Therapeutics stock price monthly change
CymaBay Therapeutics stock price quarterly change
CymaBay Therapeutics stock price yearly change
CymaBay Therapeutics key metrics
Market Cap | 2.15B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.98 |
Revenue | N/A |
EBITDA | -100.99M |
Income | -105.37M |
Revenue Q/Q | -99.71% |
Revenue Y/Y | 53.37% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCymaBay Therapeutics stock price history
CymaBay Therapeutics stock forecast
CymaBay Therapeutics financial statements
| Mar 2023 | 0 | -28.77M | |
|---|---|---|---|
| Jun 2023 | 31.01M | -808K | -2.61% |
| Sep 2023 | 0 | -33.88M | |
| Dec 2023 | 57K | -41.90M | -73512.28% |
| Sep 2025 | 15.47M | -60.58M | -391.4% |
|---|---|---|---|
| Dec 2025 | 28.29M | -78.02M | -275.78% |
| Mar 2026 | 39.03M | -42.64M | -109.24% |
| Jun 2026 | 68.87M | -19.87M | -28.86% |
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 245319000 | 141.13M | 57.53% |
|---|---|---|---|
| Jun 2023 | 226650000 | 118.24M | 52.17% |
| Sep 2023 | 451048000 | 124.85M | 27.68% |
| Dec 2023 | 434686000 | 142.43M | 32.77% |
| Mar 2023 | 6.43M | -60.64M | 93.07M |
|---|---|---|---|
| Jun 2023 | -25.43M | 719K | 1.05M |
| Sep 2023 | -26.14M | 15.46M | 248.92M |
| Dec 2023 | -27.38M | -42.10M | 2.72M |
CymaBay Therapeutics alternative data
| Aug 2023 | 60 |
|---|---|
| Sep 2023 | 60 |
| Oct 2023 | 60 |
| Nov 2023 | 60 |
| Dec 2023 | 60 |
| Jan 2024 | 60 |
| Feb 2024 | 60 |
| Mar 2024 | 101 |
| Apr 2024 | 101 |
| May 2024 | 101 |
| Jun 2024 | 101 |
| Jul 2024 | 101 |
CymaBay Therapeutics other data
-
What's the price of CymaBay Therapeutics stock today?
One share of CymaBay Therapeutics stock can currently be purchased for approximately $12.49.
-
When is CymaBay Therapeutics's next earnings date?
Unfortunately, CymaBay Therapeutics's (0I5P.L) next earnings date is currently unknown.
-
Does CymaBay Therapeutics pay dividends?
No, CymaBay Therapeutics does not pay dividends.
-
How much money does CymaBay Therapeutics make?
CymaBay Therapeutics has a market capitalization of 2.15B.
-
What is CymaBay Therapeutics's stock symbol?
CymaBay Therapeutics, Inc. is traded on the LSE under the ticker symbol "0I5P.L".
-
What is CymaBay Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of CymaBay Therapeutics?
Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does CymaBay Therapeutics have?
As Jul 2024, CymaBay Therapeutics employs 101 workers.
-
When CymaBay Therapeutics went public?
CymaBay Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is CymaBay Therapeutics's official website?
The official website for CymaBay Therapeutics is cymabay.com.
-
Where are CymaBay Therapeutics's headquarters?
CymaBay Therapeutics is headquartered at 7575 Gateway Boulevard, Newark, CA.
-
How can i contact CymaBay Therapeutics?
CymaBay Therapeutics's mailing address is 7575 Gateway Boulevard, Newark, CA and company can be reached via phone at +51 02938800.
CymaBay Therapeutics company profile:
CymaBay Therapeutics, Inc.
cymabay.comLSE
101
Medical - Pharmaceuticals
Healthcare
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Newark, CA 94560
:
ISIN: US23257D1037
:
